| 查看: 1466 | 回复: 2 | |||||||||||||||||
[交流]
Abcam 杭州 招聘高级抗体研究员
|
Position Summary: The senior antibody researcher will be responsible for development of RabMAb with best in class quality of researching hotspot and frontier targets to help our customer discover more. Essential Job Functions: Immunogen designing based on database and target info. Study on target info based on published papers, datasheet of commercialize available antibody and Swiss-prot, etc. Antibody screening experimental designing includes WB, ICC, IHC, IP and Flow, etc based on targets information and analysis the results tested by corresponding antibody screening technician. Make decisions about how to move the development forward into next step. Responsible for the whole process of antibody development until publication. Minimum Requirements/Qualifications • Rigorous academic trainings in cell biology and >=5 years’ hands-on experiences in the study of cell signaling pathways. • More than 3 years experiences and able to do trouble shooting on following laboratory techniques: IHC, ChIP, ELISA, IF/ICC, flow cytometry, western blot, etc. • Excellent reading and writing in English with good oral English • Ability to rigorous logical thinking. • Skillful communication with colleagues and teamwork guidance. • Active and initiative work attitude for making progress relative independently. • Strong willingness to contribute to bio-industry and help scientists discover more. Education Qualifications: • Minimal master degree in life sciences required. PhD or PostDoc Preferred. Education abroad a plus. If interested please send your CV to：xiuya.wang@abcam.com |
回复此楼» 猜你喜欢
售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急
已经有13人回复
-
售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急
已经有18人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.5.4,科目全,可+急
已经有18人回复
-
2027博士申请-临床检验诊断学、病原生物学、微生物方向
已经有4人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急
已经有10人回复
-
售SCI文章，我:8O.5.5.1O.54,科目全,可十急
已经有22人回复
-
越来越担心硕士毕业后没有竞争力了
已经有14人回复
-
论文的挂名怎么评判贡献？基金申请中，排名第一的挂名文章
已经有3人回复
-
申博自荐 2篇一区TOP+1篇EI+2公开发明专利 2027博士申请
已经有3人回复
-
闲聊
已经有6人回复
2楼2014-09-10 11:32:57
3楼2014-12-22 10:58:39